Fat poetry: a kingdom for PPAR gamma (Q33437489)

26 July 2017

1 reference

title

Fat poetry: a kingdom for PPAR gamma (English)

1 reference

26 July 2017

Silvia I Anghel

1

1 reference

PubMed ID

17563755

26 July 2017

Walter Wahli

series ordinal

2

1 reference

26 July 2017

1 June 2007

1 reference

26 July 2017

1 reference

26 July 2017

17

1 reference

26 July 2017

6

1 reference

26 July 2017

486-511

1 reference

https://scigraph.springernature.com/pub.10.1038/cr.2007.48

26 July 2017

0 references

cites work

Sympathetic and parasympathetic innervation of adipose tissue: metabolic implications

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

ABC of obesity. Obesity and cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Regulating adipogenesis

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

https://api.crossref.org/works/10.1038%2FCR.2007.48

1 reference

7 January 2021

Regulatory circuits controlling white versus brown adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Subcutaneous fat in normal and diseased states: 2. Anatomy and physiology of white and brown adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipocyte differentiation from the inside out

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Playing with bone and fat.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Neural crest stem and progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The adipose organ: morphological perspectives of adipose tissues.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Evidence for a role of developmental genes in the origin of obesity and body fat distribution

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Visceral Obesity in Men: Associations With Glucose Tolerance, Plasma Insulin, and Lipoprotein Levels

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A comparison of abdominal subcutaneous adipose tissue pattern in obese and lean HIV-infected women

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Insulin signaling in human visceral and subcutaneous adipose tissue in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Isolation of cDNAs for perilipins A and B: sequence and expression of lipid droplet-associated proteins of adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipocytes as regulators of energy balance and glucose homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Old fat, make way for new fat.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Human fat cell lipolysis: biochemistry, regulation and clinical role

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Chronic effects of different non-esterified fatty acids on pancreatic islets of rats

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Abdominal obesity and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Brain adipocytokine action and metabolic regulation.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose tissue as source and target for novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose tissue: a regulator of inflammation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Fat as an endocrine organ: relationship to the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose tissue and adipokines: for better or worse

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Weight-reducing effects of the plasma protein encoded by the obese gene

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Hyperleptinemia: protecting the heart from lipid overload

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Fat storage in adipocytes requires inactivation of leptin's paracrine activity: implications for treatment of human obesity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose tissue as an endocrine organ

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Effects of the obese gene product on body weight regulation in ob/ob mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Negative regulation of growth hormone receptor signaling.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Partial leptin restoration increases hypothalamic-pituitary-adrenal activity while diminishing weight loss and hyperphagia in streptozotocin diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Leptin and leptin receptor in anterior pituitary function

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adiponectin: a key adipocytokine in metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A family of tissue-specific resistin-like molecules

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Regulation of fasted blood glucose by resistin

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Disulfide-dependent multimeric assembly of resistin family hormones

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Role of resistin in obesity, insulin resistance and Type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The hormone resistin links obesity to diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Resistin release by human adipose tissue explants in primary culture

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Increased resistin blood levels are not associated with insulin resistance in patients with renal disease

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Resistin: molecular history and prognosis

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1).

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Obesity and the role of adipose tissue in inflammation and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Changes in adipocytes and dendritic cells in lymph node containing adipose depots during and after many weeks of mild inflammation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Obesity-induced inflammatory changes in adipose tissue.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Inflammation and metabolic disorders

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

TNFα expression of subcutaneous adipose tissue in obese and morbid obese females: relationship to adipocyte LPL activity and leptin synthesis

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Tumor necrosis factor-alpha induces apoptosis of human adipose cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

RETRACTED: Interleukin-6 receptor expression in contracting human skeletal muscle: regulating role of IL-6.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Central obesity and hypertensive renal disease: association between higher levels of BMI, circulating transforming growth factor beta1 and urinary albumin excretion.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Transforming growth factor beta1 release by human adipose tissue is enhanced in obesity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

PAI-1 and the metabolic syndrome: links, causes, and consequences

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The adipocyte and hemostatic balance in obesity: studies of PAI-1.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Tissue factor gene expression in the adipose tissues of obese mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipocyte functions are modulated by cell size change: potential involvement of an integrin/ERK signalling pathway

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Inflamed fat: what starts the fire?

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Obesity is associated with macrophage accumulation in adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Monocyte chemoattractant protein 1 in obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Genetics of human obesity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Lipodystrophy: lessons in lipid and energy metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A pericellular collagenase directs the 3-dimensional development of white adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

ALMNASplicing Mutation in Two Sisters with Severe Dunnigan-Type Familial Partial Lipodystrophy Type 2

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Membrane topology of the human seipin protein

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Prevalence of mutations in AGPAT2 among human lipodystrophies

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Role of CD95-Mediated Adipocyte Loss in Autoimmune Lipodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

https://api.crossref.org/works/10.1038%2FCR.2007.48

1 reference

7 January 2021

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight/obese humans.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Search for the preadipocyte progenitor cell.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The many faces of PPARgamma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Mitotic clonal expansion during preadipocyte differentiation: calpain-mediated turnover of p27.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

RNA interference of PPARgamma using fiber-modified adenovirus vector efficiently suppresses preadipocyte-to-adipocyte differentiation in 3T3-L1 cells

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Transcriptional control of adipocyte formation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

PPARalpha governs glycerol metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A mutation in the peroxisome proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A futile metabolic cycle activated in adipocytes by antidiabetic agents

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

PPAR gamma is required for placental, cardiac, and adipose tissue development

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Altered growth in male peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous mice: involvement of PPARgamma in a negative feedback regulation of growth hormone action

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Impact of the Peroxisome Proliferator Activated Receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Combining information from common type 2 diabetes risk polymorphisms improves disease prediction

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Be fit or be sick: peroxisome proliferator-activated receptors are down the road

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The Pro115Gln polymorphism within the PPAR gamma2 gene has no epidemiological impact on morbid obesity.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

PPAR gamma, 10 years later

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Peroxisome proliferator activated receptor-gamma, leptin and tumor necrosis factor-alpha mRNA expression during very low calorie diet in subcutaneous adipose tissue in obese women

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Differentiating members of the thiazolidinedione class: a focus on safety

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs).

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Selective PPARgamma modulators with improved pharmacological profiles

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Benzoyl 2-methyl indoles as selective PPARgamma modulators

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Resveratrol improves health and survival of mice on a high-calorie diet

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4).

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Constitutive and regulated expression and secretion of interferon-gamma-inducible protein 10 (IP-10/CXCL10) in human adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Adipose tissue, inflammation, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FCR.2007.48

7 January 2021

Identifiers

DOI

10.1038/CR.2007.48

1 reference

26 July 2017

1 reference

PubMed ID

17563755